Zacks Investment Research downgraded shares of HEARTWARE INTL (HTWR) from OUTPERFORM to NEUTRAL on September 01, 2014, with a target price of $95.10.
HeartWare International, Inc. along with its subsidiaries is a medical device company focused on developing and commercializing small implantable pumps for the treatment of chronic and end-stage heart failure. Its principle product, the HeartWare Ventricular Assist System, includes a left ventricular assist device, related accessories and surgical tools and is designed to provide circulatory support for patients with advanced heart failure. The company is also developing the Miniaturized Ventricular Assist Device focused on minimally invasive implantation techniques. HeartWare is also developing a portfolio of further miniaturized devices, implantable by progressively less invasive surgery. The Company's corporate headquarters are in Framingham, Massachusetts and its operating and manufacturing activities are based in Miami Lakes, Florida.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on HEARTWARE INTL (HTWR),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment